Charles Kummeth compensation by year
BIO-TECHNE Summary Compensation Table · all 9 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $800,000 | $880,000 | $911,000 | $957,000 | $1,053,000 | $1,116,000 | $1,183,000 | $1,184,200 | $1,184,200 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $2,500,044 | $3,550,140 | $3,550,008 | $3,999,925 | $4,310,652 | $4,599,864 | $5,149,692 | $5,000,108 | $5,000,028 |
| Option awards | $2,908,732 | $3,549,359 | $3,550,081 | $4,000,343 | $4,310,748 | $6,599,940 | $5,149,669 | $24,325,102 | $0 |
| Non-equity incentive | $1,221,097 | $1,053,594 | $1,610,925 | $2,008,183 | $1,767,957 | $3,537,214 | $3,856,735 | $54,092 | $596,837 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $38,241 | $43,798 | $42,860 | $45,688 | $41,425 | $36,879 | $31,452 | $21,141 | $11,880 |
| Total | $7,468,114 | $9,076,890 | $9,664,874 | $11,011,138 | $11,484,782 | $15,889,896 | $15,370,549 | $30,584,644 | $6,792,945 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-TECHNE Corp DEF 14A filed September 12, 2024, accession 0001308179-24-000703, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIO-TECHNE Corp filed document, accession 0001308179-24-000703. Every figure is read from that document and cited to the page and table it appears in. Filed September 12, 2024.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 59,095 | $4,234,157 | — |
| RSU | 35,268 | $2,526,952 | — |
| PSU | 32,064 | $2,297,386 | — |
| RSU | 7,124 | $510,435 | — |
| Option | 38,296 | — | $66.97 |
| Option | 41,752 | — | $120.46 |
| Option | 125,260 | — | $120.46 |
| Option | 600,000 | — | $94.52 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-TECHNE Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
BIO-TECHNE’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kim Kelderman | President and CEO Former President, Diagnostics and Genomics | $6,852,495 |
| Charles Kummeth · this page | Former President and CEO | $6,792,945 |
| James Hippel | Executive Vice President and CFO | $5,202,632 |
| William Geist | President, Protein Sciences | $3,647,219 |
| Matthew McManus | President, Diagnostics and Genomics | $1,994,642 |
| Shane Bohnen | Senior Vice President and General Counsel | $1,455,793 |
Board service
BIO-TECHNE board · FY2021–FY2023How this board is paid
Company policy: BIO-TECHNE pays directors a $75,000 cash retainer and $200,000 in 50% stock options, 50% restricted stock. As stated in BIO-TECHNE's FY2023 proxy.
The full BIO-TECHNE compensation record
free company briefThis page is one person within BIO-TECHNE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIO-TECHNE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-TECHNE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.